Boston Trust Walden Corp increased its stake in shares of Dolby Laboratories (NYSE:DLB – Free Report) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,098,218 shares of the electronics maker’s stock after purchasing an additional 22,404 shares during the quarter. Boston Trust Walden Corp’s holdings in Dolby Laboratories were worth $81,554,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of the stock. TD Asset Management Inc grew its stake in shares of Dolby Laboratories by 41.5% during the second quarter. TD Asset Management Inc now owns 16,700 shares of the electronics maker’s stock valued at $1,240,000 after purchasing an additional 4,900 shares during the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Dolby Laboratories during the second quarter valued at approximately $550,000. Vest Financial LLC grew its stake in shares of Dolby Laboratories by 156.1% during the second quarter. Vest Financial LLC now owns 28,942 shares of the electronics maker’s stock valued at $2,149,000 after purchasing an additional 17,640 shares during the last quarter. CWM LLC grew its stake in shares of Dolby Laboratories by 57.8% during the second quarter. CWM LLC now owns 21,752 shares of the electronics maker’s stock valued at $1,615,000 after purchasing an additional 7,967 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in shares of Dolby Laboratories by 10.9% during the second quarter. IFP Advisors Inc now owns 2,675 shares of the electronics maker’s stock valued at $201,000 after purchasing an additional 262 shares during the last quarter. 58.56% of the stock is owned by institutional investors.
Dolby Laboratories Price Performance
Shares of NYSE DLB opened at $68.80 on Tuesday. The company’s 50 day simple moving average is $72.14 and its 200 day simple moving average is $73.94. Dolby Laboratories has a fifty-two week low of $67.83 and a fifty-two week high of $89.66. The firm has a market capitalization of $6.59 billion, a P/E ratio of 25.20 and a beta of 0.92.
Dolby Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were issued a $0.33 dividend. The ex-dividend date was Tuesday, August 12th. This represents a $1.32 annualized dividend and a yield of 1.9%. Dolby Laboratories’s dividend payout ratio (DPR) is 48.35%.
Wall Street Analyst Weigh In
Several research firms have recently commented on DLB. Weiss Ratings reissued a “hold (c)” rating on shares of Dolby Laboratories in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Dolby Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. Tigress Financial increased their price target on shares of Dolby Laboratories from $112.00 to $114.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Rosenblatt Securities restated a “buy” rating and issued a $95.00 price objective on shares of Dolby Laboratories in a report on Friday, August 1st. Finally, Baird R W upgraded shares of Dolby Laboratories to a “hold” rating in a report on Friday, September 5th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.
Check Out Our Latest Analysis on Dolby Laboratories
Insider Buying and Selling at Dolby Laboratories
In other Dolby Laboratories news, CEO Kevin J. Yeaman sold 25,000 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $71.66, for a total value of $1,791,500.00. Following the sale, the chief executive officer directly owned 114,725 shares in the company, valued at approximately $8,221,193.50. This trade represents a 17.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Shriram Revankar sold 7,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $74.92, for a total transaction of $524,440.00. Following the completion of the sale, the senior vice president owned 70,435 shares in the company, valued at approximately $5,276,990.20. This trade represents a 9.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,491 shares of company stock worth $4,310,515. Company insiders own 38.39% of the company’s stock.
About Dolby Laboratories
Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.
Further Reading
- Five stocks we like better than Dolby Laboratories
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- Why Congress Is Buying Intuitive Surgical Ahead of Earnings
- What is the NASDAQ Stock Exchange?
- FICO’s Big Dip Could Be the Best Buying Chance of the Year
- How is Compound Interest Calculated?
- D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
Want to see what other hedge funds are holding DLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dolby Laboratories (NYSE:DLB – Free Report).
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.